ARCHIVES

Wyngaarden Recommendation On New Director Due Nov. 1o; Five Staff Members Nominated

This article is from The Cancer Letter archive.

Vol. 14 No. 43 | November 4, 1988

Download PDF Visit The Full Archive

Related Articles

Updated EMILIA Phase III Trial Results Confirm Increase in Overall Survival

August 31, 2012

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

September 27, 2002

Cancer Control Survey “a Flop,” Advisory committee Members Say

October 11, 1974

Taking on question of cost and outcomes, CMS turns to expert in cancer care quality.

June 3, 2005

Stand Up To Cancer Says $80 Million in Pledges Raised

September 17, 2010

House Medicare Reform Bill Takes A smaller Bite In Drug Reimbursement

June 20, 1997